Phaseline

Companies › CG Pharmaceuticals

CG Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ivaltinostat
Histone deacetylase (HDAC) inhibitor
HDACPhase 1Metastatic Pancreatic Adenocarcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05249101IvaltinostatPhase 1Metastatic Pancreatic AdenocarcinomaOncologyJun 2026

Targets

HDAC (1)

Companies with the same targets

BeBetter Med HUYABIO International

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.